Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 EPS by 6c ; Offers Guidance

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q1 EPS of $0.27, $0.06 better than the analyst estimate of $0.21. Revenue for the quarter came in at $214.27 million versus the consensus estimate of $207.12 million.

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2026 revenue of $930-945 million, versus the consensus of $913.3 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Textron Systems wins $231 million Navy contract for landing craft
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c